Rosalaura Virginia Villarreal-González, Margarita Ortega-Cisneros, Diana Estefanía Cadenas-García, Alejandra Canel-Paredes, Alira Fraga-Olvera, Angélica Delgado-Bañuelos, Germán Agustín Rico-Solís, Itzel Vianey Ochoa-García, Jaime Omar Jiménez-Sandoval, Jennifer Ramírez-Heredia, José Valentín Flores-González, Rosa María Cortés-Grimaldo, Yahvéh Zecua-Nájera
Background: Adverse drug reactions are defined as unexpected reactions, either derived from the pharmacokinetics of the treatment (Type A) or as a host immune response (Type B), resulting in harmful or undesirable manifestations in the patient following the administration of pharmacological therapy. Type B reactions are less defined and are considered a result of hypersensitivity to pharmacological treatment, categorized as immediate (within 1 to 6 hours after exposure) and delayed or non-immediate (occurring 6 hours after exposure).
Objective: A review to describe the immunological mechanisms of delayed hypersensitivity reactions to drugs.
Methods: A search of major medical databases on delayed hypersensitivity reactions to drugs was conducted. The review was limited to articles published in the period between 2013 and 2023, taking into consideration articles written in English and Spanish.
Results: The terms defining delayed hypersensitivity reactions to drugs, their classification, clinical manifestations, diagnosis, treatment algorithms, and prognosis.
Conclusions: Adverse drug reactions represent a challenge for the specialist physician, with a complex pathophysiology. A prompt diagnosis and treatment focused on the drug phenotype and its immunological expression are required to provide a multidisciplinary approach.
{"title":"[Delayed hypersensitivity reactions to drugs: Group Report of the Drug Allergy Committee of the Mexican College of Clinical Immunology and Allergy (CMICA).]","authors":"Rosalaura Virginia Villarreal-González, Margarita Ortega-Cisneros, Diana Estefanía Cadenas-García, Alejandra Canel-Paredes, Alira Fraga-Olvera, Angélica Delgado-Bañuelos, Germán Agustín Rico-Solís, Itzel Vianey Ochoa-García, Jaime Omar Jiménez-Sandoval, Jennifer Ramírez-Heredia, José Valentín Flores-González, Rosa María Cortés-Grimaldo, Yahvéh Zecua-Nájera","doi":"10.29262/ram.v71i3.1299","DOIUrl":"10.29262/ram.v71i3.1299","url":null,"abstract":"<p><strong>Background: </strong>Adverse drug reactions are defined as unexpected reactions, either derived from the pharmacokinetics of the treatment (Type A) or as a host immune response (Type B), resulting in harmful or undesirable manifestations in the patient following the administration of pharmacological therapy. Type B reactions are less defined and are considered a result of hypersensitivity to pharmacological treatment, categorized as immediate (within 1 to 6 hours after exposure) and delayed or non-immediate (occurring 6 hours after exposure).</p><p><strong>Objective: </strong>A review to describe the immunological mechanisms of delayed hypersensitivity reactions to drugs.</p><p><strong>Methods: </strong>A search of major medical databases on delayed hypersensitivity reactions to drugs was conducted. The review was limited to articles published in the period between 2013 and 2023, taking into consideration articles written in English and Spanish.</p><p><strong>Results: </strong>The terms defining delayed hypersensitivity reactions to drugs, their classification, clinical manifestations, diagnosis, treatment algorithms, and prognosis.</p><p><strong>Conclusions: </strong>Adverse drug reactions represent a challenge for the specialist physician, with a complex pathophysiology. A prompt diagnosis and treatment focused on the drug phenotype and its immunological expression are required to provide a multidisciplinary approach.</p>","PeriodicalId":101421,"journal":{"name":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","volume":"71 3","pages":"169-188"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142776225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objetives: To describe the events supposedly attributable to immunization with the Pfizer-BioNTech® COVID-19 vaccine in children aged 5 to 17 years in the state of Puebla, Mexico.
Methods: Observational, cross-sectional and descriptive study carried out based on the analysis of reports of events supposedly attributable to immunization in children aged 5 to 17 years, who received the vaccine with the BNT162b2 mRNA platform for COVID-19, since January. to December 2022. Percentages, frequencies, averages, standard deviations and medians were used for statistical analysis. The Statistical Package for the Social Sciences 23 program was implemented.
Results: 1,993,373 doses of the BNT162b2 vaccine were administered. 52 events presumed to be attributable to vaccination or immunization were reported. An annual rate of 2.6 per 100,000 doses applied was estimated. The age distribution recorded a median of 10.50 years (SD: 3.53). There were 56% women and 44% men; The most frequent symptoms were: dizziness, nausea, vomiting and pain at the vaccine application site. 2 cases of seizures and 1 of flaccid paralysis were reported.
Conclusions: The safety of vaccines against SARS-CoV-2 requires an improvement in strategies for epidemiological surveillance (passive and active), with a more robust approach to guarantee safe vaccination.
{"title":"[Adverse events from the Pfizer-BioNTech® COVID-19vaccine in children 5-17 years old].","authors":"María Del Rocío Hernández Morales, Margarita Aguirre Barbosa, Eleazar Mancilla Hernández, Sandra Aidée González Hidalgo, Estefanía Alavez López, Sandra Maldonado Castañeda","doi":"10.29262/ram.v71i3.1387","DOIUrl":"10.29262/ram.v71i3.1387","url":null,"abstract":"<p><strong>Objetives: </strong>To describe the events supposedly attributable to immunization with the Pfizer-BioNTech® COVID-19 vaccine in children aged 5 to 17 years in the state of Puebla, Mexico.</p><p><strong>Methods: </strong>Observational, cross-sectional and descriptive study carried out based on the analysis of reports of events supposedly attributable to immunization in children aged 5 to 17 years, who received the vaccine with the BNT162b2 mRNA platform for COVID-19, since January. to December 2022. Percentages, frequencies, averages, standard deviations and medians were used for statistical analysis. The Statistical Package for the Social Sciences 23 program was implemented.</p><p><strong>Results: </strong>1,993,373 doses of the BNT162b2 vaccine were administered. 52 events presumed to be attributable to vaccination or immunization were reported. An annual rate of 2.6 per 100,000 doses applied was estimated. The age distribution recorded a median of 10.50 years (SD: 3.53). There were 56% women and 44% men; The most frequent symptoms were: dizziness, nausea, vomiting and pain at the vaccine application site. 2 cases of seizures and 1 of flaccid paralysis were reported.</p><p><strong>Conclusions: </strong>The safety of vaccines against SARS-CoV-2 requires an improvement in strategies for epidemiological surveillance (passive and active), with a more robust approach to guarantee safe vaccination.</p>","PeriodicalId":101421,"journal":{"name":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","volume":"71 3","pages":"139-145"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142776200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Víctor Fernando Muñoz-Estrada, Edwin Daniel Maldonado-Domínguez
Background: Urticaria is characterized by the transient appearance of hives, angioedema, or both. Acute urticaria lasts less than 6 weeks. The origin is idiopathic in more than 50% of cases, and the most frequent triggers are infectious processes, drugs and foods.
Objective: Describe the origin, pathophysiology and treatment of patients with acute urticaria.
Methods: A bibliographic search of articles was carried out in PubMed, where the Mesh terms: "Urticaria", "Angioedema" and "Antihistamines" were included and those with information related to acute urticaria were chosen, among those published from 2014 to 2023. In addition, the inclusion of some publications from previous years was considered, due to their relevance for this review.
Results: The initial search returned 135 articles, but only 104 were used for the final manuscript.
Conclusions: Acute urticaria is one of the most frequent reasons for consultation in the Allergology and Dermatology emergency services. Although there are multiple etiological factors, most cases are idiopathic, so it should not be overdiagnosed as an allergic reaction.
{"title":"[Acute urticaria].","authors":"Víctor Fernando Muñoz-Estrada, Edwin Daniel Maldonado-Domínguez","doi":"10.29262/ram.v71i3.1364","DOIUrl":"https://doi.org/10.29262/ram.v71i3.1364","url":null,"abstract":"<p><strong>Background: </strong>Urticaria is characterized by the transient appearance of hives, angioedema, or both. Acute urticaria lasts less than 6 weeks. The origin is idiopathic in more than 50% of cases, and the most frequent triggers are infectious processes, drugs and foods.</p><p><strong>Objective: </strong>Describe the origin, pathophysiology and treatment of patients with acute urticaria.</p><p><strong>Methods: </strong>A bibliographic search of articles was carried out in PubMed, where the Mesh terms: \"Urticaria\", \"Angioedema\" and \"Antihistamines\" were included and those with information related to acute urticaria were chosen, among those published from 2014 to 2023. In addition, the inclusion of some publications from previous years was considered, due to their relevance for this review.</p><p><strong>Results: </strong>The initial search returned 135 articles, but only 104 were used for the final manuscript.</p><p><strong>Conclusions: </strong>Acute urticaria is one of the most frequent reasons for consultation in the Allergology and Dermatology emergency services. Although there are multiple etiological factors, most cases are idiopathic, so it should not be overdiagnosed as an allergic reaction.</p>","PeriodicalId":101421,"journal":{"name":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","volume":"71 3","pages":"189-204"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142776198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lucía Moreno-Lozano, Teresa de Aramburu-Mera, Carmen Bermúdez-Hormigo
Background: Allergic sensitization to topical antimicrobial treatments is a well-known problem. Furacin® is one of the most widely used in our environment. It contains 0.2% nitrofurazone and polyethylene glycol (PEG) as a vehicle.
Case report: 57-year-old male with no history of interest. He presented skin rash, blisters, and serous exudate 2-3 days after starting treatment with Furacin® (applied to an infected skin wound). Epicutaneous tests were performed with a true test battery, nitrofurantoin 1% in petrolatum, PEG15000 and 4000 1% in petrolatum, pure PEG 400, PEG monomethyl ether 350 1% in water. Positive result at 96 hours for nitrofurantoin.
Conclusion: Nitrofurazone is widely used as a topical antibiotic because of its bactericidal spectrum. It (including its excipients) should be considered in case of adverse reactions after application.
{"title":"[Allergic contact dermatitis due to Furacin®].","authors":"Lucía Moreno-Lozano, Teresa de Aramburu-Mera, Carmen Bermúdez-Hormigo","doi":"10.29262/ram.v71i2.1246","DOIUrl":"https://doi.org/10.29262/ram.v71i2.1246","url":null,"abstract":"<p><strong>Background: </strong>Allergic sensitization to topical antimicrobial treatments is a well-known problem. Furacin® is one of the most widely used in our environment. It contains 0.2% nitrofurazone and polyethylene glycol (PEG) as a vehicle.</p><p><strong>Case report: </strong>57-year-old male with no history of interest. He presented skin rash, blisters, and serous exudate 2-3 days after starting treatment with Furacin® (applied to an infected skin wound). Epicutaneous tests were performed with a true test battery, nitrofurantoin 1% in petrolatum, PEG15000 and 4000 1% in petrolatum, pure PEG 400, PEG monomethyl ether 350 1% in water. Positive result at 96 hours for nitrofurantoin.</p><p><strong>Conclusion: </strong>Nitrofurazone is widely used as a topical antibiotic because of its bactericidal spectrum. It (including its excipients) should be considered in case of adverse reactions after application.</p>","PeriodicalId":101421,"journal":{"name":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","volume":"71 2","pages":"128-130"},"PeriodicalIF":0.0,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brenda Guendulain-Velázquez, Patricia María O'Farrill-Romanillos
Objective: Estimate the prevalence of dermatological manifestations in Mexican patients with common variable immunodeficiency.
Methods: Cross-sectional and retrospective study, based on the analysis of records of patients with a diagnosis of common variable immunodeficiency, treated at the Siglo XXI National Medical Center (Mexican Social Security Institute), according to the criteria of the European Society of Immunodeficiencies (ESID). and of which only 3 had a genetic diagnosis with the following mutations: IRF2, CTLA4 and PIK-3, belonging to the Immunodeficiency Clinic of the National Medical Center Siglo XXI (IMSS), to evaluate dermatological manifestations, review of laboratory tests: IgA, IgM, IgG and type of replacement therapy with Immunoglobulin. The statistical analysis was carried out with the SPSS program; Descriptive statistics were used to analyze the data, according to the type of variable to be analyzed.
Results: 36 patients were included, of which 55.5% were women; with median age 34 years (18-94). The prevalence of dermatological manifestations was 70% (n = 25). 30.5% had a history of infectious dermatosis and 39.5% had a history of non-infectious dermatosis. The most common dermatosis was irritant contact dermatitis in 13.8% of patients. All received replacement therapy with human immunoglobulin, 33.3% intravenously and the rest subcutaneously.
Conclusions: Common variable immunodeficiency is an inborn error of immunity, with different clinical manifestations in various organs and systems (the skin is one of these). Dermatological manifestations are not usually described in patients with common variable immunodeficiency; However, it is important to identify them due to their relationship with certain complications (increased risk of superinfection), due to skin disruption and biological therapies.
目的估计墨西哥常见可变免疫缺陷病患者皮肤病的发病率:根据欧洲免疫缺陷协会(ESID)的标准,对在 Siglo XXI 国家医疗中心(墨西哥社会保障局)接受治疗并确诊为常见可变免疫缺陷患者的记录进行分析:IRF2、CTLA4 和 PIK-3,隶属于国家二十一世纪医疗中心(IMSS)的免疫缺陷诊所,以评估皮肤病表现,审查实验室检测结果:IgA、IgM、IgG 和免疫球蛋白替代疗法的类型。统计分析使用 SPSS 程序进行;根据待分析变量的类型,使用描述性统计对数据进行分析:共纳入 36 名患者,其中 55.5% 为女性,中位年龄为 34 岁(18-94 岁)。皮肤病的发病率为 70%(25 人)。30.5%的患者有感染性皮肤病病史,39.5%的患者有非感染性皮肤病病史。最常见的皮肤病是刺激性接触性皮炎,占患者总数的 13.8%。所有患者都接受了人免疫球蛋白替代治疗,其中33.3%的患者接受静脉注射,其余患者接受皮下注射:结论:常见变异性免疫缺陷是一种先天性免疫缺陷,在不同器官和系统(皮肤就是其中之一)有不同的临床表现。常见可变免疫缺陷症患者通常不会出现皮肤表现;然而,由于皮肤破坏和生物疗法会导致某些并发症(增加超级感染的风险),因此识别皮肤表现非常重要。
{"title":"[Prevalence of dermatological manifestations in common variable immunodeficiency patients].","authors":"Brenda Guendulain-Velázquez, Patricia María O'Farrill-Romanillos","doi":"10.29262/ram.v71i2.1296","DOIUrl":"https://doi.org/10.29262/ram.v71i2.1296","url":null,"abstract":"<p><strong>Objective: </strong>Estimate the prevalence of dermatological manifestations in Mexican patients with common variable immunodeficiency.</p><p><strong>Methods: </strong>Cross-sectional and retrospective study, based on the analysis of records of patients with a diagnosis of common variable immunodeficiency, treated at the Siglo XXI National Medical Center (Mexican Social Security Institute), according to the criteria of the European Society of Immunodeficiencies (ESID). and of which only 3 had a genetic diagnosis with the following mutations: IRF2, CTLA4 and PIK-3, belonging to the Immunodeficiency Clinic of the National Medical Center Siglo XXI (IMSS), to evaluate dermatological manifestations, review of laboratory tests: IgA, IgM, IgG and type of replacement therapy with Immunoglobulin. The statistical analysis was carried out with the SPSS program; Descriptive statistics were used to analyze the data, according to the type of variable to be analyzed.</p><p><strong>Results: </strong>36 patients were included, of which 55.5% were women; with median age 34 years (18-94). The prevalence of dermatological manifestations was 70% (n = 25). 30.5% had a history of infectious dermatosis and 39.5% had a history of non-infectious dermatosis. The most common dermatosis was irritant contact dermatitis in 13.8% of patients. All received replacement therapy with human immunoglobulin, 33.3% intravenously and the rest subcutaneously.</p><p><strong>Conclusions: </strong>Common variable immunodeficiency is an inborn error of immunity, with different clinical manifestations in various organs and systems (the skin is one of these). Dermatological manifestations are not usually described in patients with common variable immunodeficiency; However, it is important to identify them due to their relationship with certain complications (increased risk of superinfection), due to skin disruption and biological therapies.</p>","PeriodicalId":101421,"journal":{"name":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","volume":"71 2","pages":"91-95"},"PeriodicalIF":0.0,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniela Rivero-Yeverino, Jonathan Higgins Payan-Diaz, Aída Inés López-García, José Sergio Papaqui-Tapia, Chrystopherson Gengyny Caballero-López, Juan Jesús Ríos-López, Carlos David López-Romero, Johav Yael Sánchez-Villalobos, Elisa Ortega Jordá-Rodríguez, Armando Álvarez-Rivera, Erika Villada-Villada
Objetives: To evaluate the impact of cholecalciferol (D₃) supplementation using clinical and paraclinical variables in patients with RA and vitamin D insufficiency and deficiency.
Methods: A randomized, double-blind, placebo-controlled study included patients from 5 to 40 years with a diagnosis of RA and vitamin D insufficiency and deficiency. They were supplemented for 8 weeks with 4000 or 5000 IU, depending on age. Total nasal symptoms score (TNSS) was measured monthly and 25(OH)D₃ levels at baseline and at the end of the study.
Results: A total of 31 patients were included, with a mean age of 18.19 years. In the active group, there was a significant improvement in symptomatology with respect to the TNSS score and an increase in serum vitamin D levels (p < 0.01). There were no adverse reactions with cholecalciferol or placebo.
Conclusions: Supplementing patients with vitamin D₃, at the evaluated dose, together with conventional treatent for allergic rhinitis results in symptoms and quality of life improvement in patients with this disease.
{"title":"[Therapeutic effect of vitamin D supplementation in mexican patients with allergic rhinitis].","authors":"Daniela Rivero-Yeverino, Jonathan Higgins Payan-Diaz, Aída Inés López-García, José Sergio Papaqui-Tapia, Chrystopherson Gengyny Caballero-López, Juan Jesús Ríos-López, Carlos David López-Romero, Johav Yael Sánchez-Villalobos, Elisa Ortega Jordá-Rodríguez, Armando Álvarez-Rivera, Erika Villada-Villada","doi":"10.29262/ram.v71i2.1282","DOIUrl":"10.29262/ram.v71i2.1282","url":null,"abstract":"<p><strong>Objetives: </strong>To evaluate the impact of cholecalciferol (D₃) supplementation using clinical and paraclinical variables in patients with RA and vitamin D insufficiency and deficiency.</p><p><strong>Methods: </strong>A randomized, double-blind, placebo-controlled study included patients from 5 to 40 years with a diagnosis of RA and vitamin D insufficiency and deficiency. They were supplemented for 8 weeks with 4000 or 5000 IU, depending on age. Total nasal symptoms score (TNSS) was measured monthly and 25(OH)D₃ levels at baseline and at the end of the study.</p><p><strong>Results: </strong>A total of 31 patients were included, with a mean age of 18.19 years. In the active group, there was a significant improvement in symptomatology with respect to the TNSS score and an increase in serum vitamin D levels (p < 0.01). There were no adverse reactions with cholecalciferol or placebo.</p><p><strong>Conclusions: </strong>Supplementing patients with vitamin D₃, at the evaluated dose, together with conventional treatent for allergic rhinitis results in symptoms and quality of life improvement in patients with this disease.</p>","PeriodicalId":101421,"journal":{"name":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","volume":"71 2","pages":"85-90"},"PeriodicalIF":0.0,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Determine the level of knowledge of mothers of children under 5 years of age about vaccination schedule.
Methods: Cross-sectional, observational, descriptive, and analytical study, carried out in the Family Medicine Unit 1 of Orizaba, Veracruz, in which two questionnaires were applied to mothers of children under 5 years of age, one prepared by PAHO that qualifies attitudes. of parents about vaccines, and another that evaluates knowledge of immunizations. Absolute frequencies and percentages were estimated; and the association with Pearson's X2 was determined.
Results: A total of 138 women were registered, with age limits of 18 to 48 years. The level of knowledge was high (70.3%) and was related to the age, education (p = 0.00) and occupation (p = 0.03) of the mothers. The highest frequencies were for housewives (47.1%), professionals (3.5%), married (60.2%) and of the Catholic religion (81.2%).
Conclusions: This study confirms the null hypothesis, which indicates that 70.3% have high knowledge about vaccination, and it is associated with the age, education, and occupation of the mothers.
{"title":"[Knowledge of mothers of children under 5 years of age about vaccination schedule].","authors":"Diana Paola Gallardo-Martínez, Jaime Omar Jiménez-Sandoval","doi":"10.29262/ram.v71i2.1298","DOIUrl":"10.29262/ram.v71i2.1298","url":null,"abstract":"<p><strong>Objective: </strong>Determine the level of knowledge of mothers of children under 5 years of age about vaccination schedule.</p><p><strong>Methods: </strong>Cross-sectional, observational, descriptive, and analytical study, carried out in the Family Medicine Unit 1 of Orizaba, Veracruz, in which two questionnaires were applied to mothers of children under 5 years of age, one prepared by PAHO that qualifies attitudes. of parents about vaccines, and another that evaluates knowledge of immunizations. Absolute frequencies and percentages were estimated; and the association with Pearson's <i>X</i><sup>2</sup> was determined.</p><p><strong>Results: </strong>A total of 138 women were registered, with age limits of 18 to 48 years. The level of knowledge was high (70.3%) and was related to the age, education (p = 0.00) and occupation (p = 0.03) of the mothers. The highest frequencies were for housewives (47.1%), professionals (3.5%), married (60.2%) and of the Catholic religion (81.2%).</p><p><strong>Conclusions: </strong>This study confirms the null hypothesis, which indicates that 70.3% have high knowledge about vaccination, and it is associated with the age, education, and occupation of the mothers.</p>","PeriodicalId":101421,"journal":{"name":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","volume":"71 2","pages":"108-113"},"PeriodicalIF":0.0,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sandra Nora González-Díaz, Alejandra Macías-Weinmann, Cindy Elizabeth De Lira-Quezada, Valeria Gonzalez-Gonzalez, Hilda Hernández-Sánchez, Rosa Ivett Guzmán-Avilán, Andrés Noyola-Pérez, Carlos Macouzet-Sánchez
Objective: Report the prevalence and severity of the most common allergic diseases in children living in Monterrey, México.
Methods: Cross-sectional multi-center survey on the most common allergic diseases, completed by parents of 6-7-year-old children and by 13-14- year-old adolescents in the Monterrey metropolitan area, between January 2018 and December 2019.
Results: A total of 3,044 questionnaires were eligible for the analysis. Among children between 6-7 years old, 30.2% (n = 143/473) presented wheezing at any time in their life; with a higher prevalence in the male population. In the adolescent group, 26.4% reported having experienced wheezing at some point in their life, with a slight predominance in the female group (54.9%).
Conclusions: Knowing the prevalence of allergic diseases in our population gives us tools to generate strategies that allow us to provide the best quality healthcare to our patients.
{"title":"[Epidemiological profile of allergic respiratory disease in Mexican children].","authors":"Sandra Nora González-Díaz, Alejandra Macías-Weinmann, Cindy Elizabeth De Lira-Quezada, Valeria Gonzalez-Gonzalez, Hilda Hernández-Sánchez, Rosa Ivett Guzmán-Avilán, Andrés Noyola-Pérez, Carlos Macouzet-Sánchez","doi":"10.29262/ram.v71i2.1301","DOIUrl":"10.29262/ram.v71i2.1301","url":null,"abstract":"<p><strong>Objective: </strong>Report the prevalence and severity of the most common allergic diseases in children living in Monterrey, México.</p><p><strong>Methods: </strong>Cross-sectional multi-center survey on the most common allergic diseases, completed by parents of 6-7-year-old children and by 13-14- year-old adolescents in the Monterrey metropolitan area, between January 2018 and December 2019.</p><p><strong>Results: </strong>A total of 3,044 questionnaires were eligible for the analysis. Among children between 6-7 years old, 30.2% (n = 143/473) presented wheezing at any time in their life; with a higher prevalence in the male population. In the adolescent group, 26.4% reported having experienced wheezing at some point in their life, with a slight predominance in the female group (54.9%).</p><p><strong>Conclusions: </strong>Knowing the prevalence of allergic diseases in our population gives us tools to generate strategies that allow us to provide the best quality healthcare to our patients.</p>","PeriodicalId":101421,"journal":{"name":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","volume":"71 2","pages":"96-107"},"PeriodicalIF":0.0,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Melisa Zavala-Rodríguez, Marco Antonio Martínez-Triana, María Del Rocío Hernández-Morales, Rubén Peña-Vélez
Background: Acute liver failure in pediatric age is a serious multisystem disease, characterized by a failure of the synthesis and detoxification function of the liver. Among the etiologies, viral infection should be investigated. Treatment is supportive and some cases require liver transplantation.
Case report: A 2-year-old girl was admitted for acute liver failure. The PCR viral panel was positive for Adenovirus 41 and IgG antibodies to SARS-CoV-2 were also found. Supportive treatment was started without improvement, so intravenous immunoglobulin was administered, with resolution of the liver failure.
Conclusions: Immunoglobulin has immunomodulatory mechanisms in children with severe acute hepatitis of infectious etiology, so in some cases, its administration can be considered as adjuvant therapy.
{"title":"[Adenovirus-related acute liver failure treated with intravenous immunoglobulin].","authors":"Melisa Zavala-Rodríguez, Marco Antonio Martínez-Triana, María Del Rocío Hernández-Morales, Rubén Peña-Vélez","doi":"10.29262/ram.v71i2.1275","DOIUrl":"https://doi.org/10.29262/ram.v71i2.1275","url":null,"abstract":"<p><strong>Background: </strong>Acute liver failure in pediatric age is a serious multisystem disease, characterized by a failure of the synthesis and detoxification function of the liver. Among the etiologies, viral infection should be investigated. Treatment is supportive and some cases require liver transplantation.</p><p><strong>Case report: </strong>A 2-year-old girl was admitted for acute liver failure. The PCR viral panel was positive for Adenovirus 41 and IgG antibodies to SARS-CoV-2 were also found. Supportive treatment was started without improvement, so intravenous immunoglobulin was administered, with resolution of the liver failure.</p><p><strong>Conclusions: </strong>Immunoglobulin has immunomodulatory mechanisms in children with severe acute hepatitis of infectious etiology, so in some cases, its administration can be considered as adjuvant therapy.</p>","PeriodicalId":101421,"journal":{"name":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","volume":"71 2","pages":"131-134"},"PeriodicalIF":0.0,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}